R-Health

r-health.md

R-Health delivers more effective care and a better patient experience – all at a lower cost. We partner with employers, insurance companies, and healthcare brokers to offer primary care that’s truly collaborative. We deliver value-based healthcare two ways: R-Health Accountable Care, our commercial ACO, and R-Health Direct Primary Care, our innovative membership-based model that provides members with the care they deserve.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

AMYLYX PHARMACEUTICALS ANNOUNCES ALBRIOZA™ IS NOW AVAILABLE IN CANADA FOR THE TREATMENT OF ALS

Amylyx Pharmaceuticals, Inc | August 01, 2022

news image

Amylyx Pharmaceuticals, Inc. announced that ALBRIOZA™ is now commercially available in Canada for people living with amyotrophic lateral sclerosis. ALBRIOZA is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments. In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS. “We have remained steadfast in our commitment ...

Read More

Pharmacy Market

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Novartis | December 17, 2020

news image

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More

Pharmacy Market

ORBIT DISCOVERY AND WUXI APPTEC SIGN AGREEMENT TO ACCESS PEPTIDE DISCOVERY AND OPTIMISATION TECHNOLOGIES

Orbit Discovery | March 08, 2022

news image

Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide p...

Read More

Business Insights

LIFESPIN LAUNCHES COMMERCIAL ACCESS TO ITS METABOLIC PROFILER SOFTWARE AND DATABASE FOR PHARMA AND BIOBANK SERVICES

Lifespin | September 16, 2022

news image

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced that it has launched a new commercial service that, for the first time, will provide the pharmaceutical and biobanking industry with access to Lifespin’s proprietary metabolic database, along with its advanced interpretive software to assist in various phases of drug research, development, and manufacturing. Immediate applications of Lifespin’s commercial services will include quality c...

Read More
news image

Business Insights

AMYLYX PHARMACEUTICALS ANNOUNCES ALBRIOZA™ IS NOW AVAILABLE IN CANADA FOR THE TREATMENT OF ALS

Amylyx Pharmaceuticals, Inc | August 01, 2022

Amylyx Pharmaceuticals, Inc. announced that ALBRIOZA™ is now commercially available in Canada for people living with amyotrophic lateral sclerosis. ALBRIOZA is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments. In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS. “We have remained steadfast in our commitment ...

Read More
news image

Pharmacy Market

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Novartis | December 17, 2020

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More
news image

Pharmacy Market

ORBIT DISCOVERY AND WUXI APPTEC SIGN AGREEMENT TO ACCESS PEPTIDE DISCOVERY AND OPTIMISATION TECHNOLOGIES

Orbit Discovery | March 08, 2022

Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide p...

Read More
news image

Business Insights

LIFESPIN LAUNCHES COMMERCIAL ACCESS TO ITS METABOLIC PROFILER SOFTWARE AND DATABASE FOR PHARMA AND BIOBANK SERVICES

Lifespin | September 16, 2022

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced that it has launched a new commercial service that, for the first time, will provide the pharmaceutical and biobanking industry with access to Lifespin’s proprietary metabolic database, along with its advanced interpretive software to assist in various phases of drug research, development, and manufacturing. Immediate applications of Lifespin’s commercial services will include quality c...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us